Role of ranitidine in negative symptoms of schizophrenia--an open label study
- PMID: 25193506
- DOI: 10.1016/j.ajp.2014.08.005
Role of ranitidine in negative symptoms of schizophrenia--an open label study
Abstract
In this open label study, 75 patients with a diagnosis of schizophrenia were randomized to three groups of 25 each, receiving 150mg/day ranitidine, 300mg/day ranitidine and receiving only olanzapine. They were rated on PANSS at baseline, 4 and 8 weeks. There was a significant reduction in the scores of negative scale in patients receiving 300mg/day ranitidine in comparison to patients not receiving ranitidine at the end of 4 weeks but was not seen again when assessed at the end of 8 weeks. Though effective in reducing the negative symptoms, the effect was not sustained due to the tolerance to the actions of ranitidine.
Keywords: H2 blockers; Histamine; Negative symptoms.
Copyright © 2014 Elsevier B.V. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
